Overview

A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A randomised phase III, double-blind, placebo-controlled trial with 2:1 (regorafenib : placebo)
Phase:
Phase 3
Details
Lead Sponsor:
Australasian Gastro-Intestinal Trials Group
Collaborators:
Academic and Community Cancer Research United
Canadian Cancer Trials Group
National Health and Medical Research Council, Australia